Skip to main content
. 2020 Oct 16;31(19-20):1043–1053. doi: 10.1089/hum.2020.156

Table 2.

Safety issues in gene therapy products using genome-editing techniques

• Off-target effects
• On-target mutagenesis
• Chromosomal changes (translocation/inversion/deletion)
• P53 mutation
• Immunogenicity of nucleases
• Germline modification